Goodwin (JD Supra Russia)

Russian Pharma Company Biocad Obtains European Certification for Biosimilars to Treat Cancer
On March 30, 2020, Russian pharmaceutical company, Biocad, announced that it and its partner, ICM d.o.o., recently obtained European registration certification in Bosnia and Herzegovina for two cancer treatment biosimilars: Acellbia (rituximab), a biosimilar of Roche’s MabThera®, and Herticad (trastuzumab), a biosimilar of Roche’s Herceptin®. According to Biocad, the registration certificate is

Request a trial to view additional results